Pharma Only Slightly Winded By Hurricane Sandy
This article was originally published in The Pink Sheet Daily
While most of the East Coast of the U.S. continues to struggle with the aftereffects of Hurricane Sandy, pharmaceutical industry operations are back to normal and the companies are doing what they can to help out.
You may also be interested in...
FDA will extend user fee goal dates as needed to account for the loss of two days in review cycles resulting from the government office shutdown. The extreme weather conditions led to cancellation of three advisory committees during the week of Oct. 29.
As the East Coast braces for the impact of Hurricane Sandy, companies choose the safety of their employees over keeping financial releases on schedule.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.